Company description

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has the proven expertise, superior technologies and flexible solutions at the right scale to help ensure successful product development, launch, tech transfer and global reliable supply. Our team of nearly 13,000, including approximately 2,400 scientists at over 35 sites, develops more than 700 projects and helps launch over 200 products every year. We produce +72 billion doses of +7,000 products for more than 1,000 customers – or 1 in 20 doses taken by patients globally. We partner with 87 of the top 100 global pharmaceutical marketers, to 24 of 25 biological marketers, to 21 of 25 leading consumer health marketers, to thousands of small innovators globally. Our passion is to help unlock the full potential of your product.

More products better treatments reliably supplied ™

Quick facts

Sales markets Western Europe; Eastern Europe; Asia; Australia; North America; Central/South America
Affiliated categories: Analytical Development |Antibody Drug Conjugates (ADCs) |API Contract Manufacturing More

Upcoming events

13 oct 2020

CPhI Worldwide 2020

13 - 15 October 2020 Milan, Italy Visit us at stand 2F10 Book a meeting See our Exhibitor Profile   See full Exhibitor List

Recently at

5 nov 2019

CPhI Worldwide 2019

5-7 November 2019 Frankfurt, Germany We were at stand 121A82 See our Exhibitor Profile   See full Exhibitor List
30 apr 2019

CPhI North America 2019

30 April - 2 May 2019 Chicago, USA We were at stand 1206 See our Exhibitor Profile   See full Exhibitor List

News about Catalent

Catalent expands beauty and plant-based consumer health softgel capabilities

30 Jun 2020

Catalent expands beauty and plant-based consumer health softgel capabilities

Two company sites - one in Canada, the other in Brazil - receive new softgel encapsulation lines to service local customer demand.

Read more

22 Jun 2020

Catalent and ViralClear Pharmaceuticals partner on potential COVID-19 treatment

The CDMO will work on developing a solution and a solid oral dosage form of ViralClear's merimepodib.

Read more

15 Jun 2020

Catalent inks deal with AstraZeneca to manufacture COVID-19 vaccine candidate

The company's Anagni, Italy facility will prepare to supply hundreds of millions of doses of the vaccine candidate if it's approved.

Read more

29 Apr 2020

Catalent to manufacture J&J's lead COVID-19 vaccine candidate

Collaboration includes joint investment and tech transfer to prepare for rapid scale-up and segregated cGMP commercial manufacturing capacity.

Read more

Contact information




View all contact information